319 related articles for article (PubMed ID: 16129903)
1. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer.
Atreya R; Neurath MF
Clin Rev Allergy Immunol; 2005 Jun; 28(3):187-96. PubMed ID: 16129903
[TBL] [Abstract][Full Text] [Related]
2. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
[TBL] [Abstract][Full Text] [Related]
3. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 trans-signaling in inflammatory bowel disease.
Mitsuyama K; Sata M; Rose-John S
Cytokine Growth Factor Rev; 2006 Dec; 17(6):451-61. PubMed ID: 17045835
[TBL] [Abstract][Full Text] [Related]
6. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis.
Mudter J; Wirtz S; Galle PR; Neurath MF
Pathobiology; 2002-2003; 70(3):170-6. PubMed ID: 12571422
[TBL] [Abstract][Full Text] [Related]
7. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
Waldner MJ; Neurath MF
Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 therapy for Crohn's disease.
Ito H
Curr Pharm Des; 2003; 9(4):295-305. PubMed ID: 12570822
[TBL] [Abstract][Full Text] [Related]
13. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.
Fuss IJ; Neurath M; Boirivant M; Klein JS; de la Motte C; Strong SA; Fiocchi C; Strober W
J Immunol; 1996 Aug; 157(3):1261-70. PubMed ID: 8757634
[TBL] [Abstract][Full Text] [Related]
14. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance.
Mudter J; Neurath MF
Inflamm Bowel Dis; 2007 Aug; 13(8):1016-23. PubMed ID: 17476678
[TBL] [Abstract][Full Text] [Related]
15. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
Neurath MF; Finotto S
Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
[TBL] [Abstract][Full Text] [Related]
16. Triptolide induces suppressor of cytokine signaling-3 expression and promotes lamina propria mononuclear cells apoptosis in Crohn's colitis.
Li Y; Tian Y; Zhu W; Gong J; Zhang W; Yu C; Gu L; Li N; Li J
Int Immunopharmacol; 2013 Jun; 16(2):268-74. PubMed ID: 23643741
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
Neurath MF
Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
[TBL] [Abstract][Full Text] [Related]
18. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.
Allocca M; Jovani M; Fiorino G; Schreiber S; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1508-21. PubMed ID: 24102406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
